Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing T… Read more
Tarsus Pharmaceuticals Inc (TARS) - Total Liabilities
Latest total liabilities as of September 2025: $199.48 Million USD
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has total liabilities worth $199.48 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tarsus Pharmaceuticals Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Tarsus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tarsus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing BDStar Navigation Co Ltd
SHE:002151
|
China | CN¥1.16 Billion |
|
Suzhou Novosense Microelectronics Co. Ltd.
SHG:688052
|
China | CN¥1.80 Billion |
|
Marel hf
PINK:MRRLF
|
USA | $1.53 Billion |
|
Infocom Corporation
PINK:IFFOF
|
USA | $18.17 Billion |
|
Jilin Power Share Co Ltd
SHE:000875
|
China | CN¥60.72 Billion |
|
Teradata Corp
NYSE:TDC
|
USA | $1.54 Billion |
|
Newmark Group Inc
NASDAQ:NMRK
|
USA | $3.84 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Tarsus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tarsus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tarsus Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Tarsus Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $152.46 Million | +122.56% |
| 2023-12-31 | $68.50 Million | +95.93% |
| 2022-12-31 | $34.96 Million | +187.12% |
| 2021-12-31 | $12.18 Million | +103.22% |
| 2020-12-31 | $5.99 Million | -90.68% |
| 2019-12-31 | $64.32 Million | +1618.43% |
| 2018-12-31 | $3.74 Million | -- |